ReviewCurrent hematologic malignancy reports2011
Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies.
Review in Current hematologic malignancy reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas.American journal of hematology · 2020Trial
- Case-Based Insights into Enteropathy-Associated T-Cell Lymphoma-Single-Center Experience.Hematology reports · 2025Article
- Incidence trends and survival analysis of enteropathy-associated T-cell lymphoma.Frontiers in immunology · 2025Article
- Malignant complications of celiac disease: a case series and review of the literature.Journal of medical case reports · 2022Review
- Surgical management of monomorphic epitheliotropic intestinal T-cell lymphoma followed by chemotherapy and stem-cell transplant: A case report and review of the literature.World journal of gastrointestinal oncology · 2022Article
- Tonsillar Extraintestinal Enteropathy-Associated T-Cell Lymphoma in a Patient With Celiac Disease.ACG case reports journal · 2022Article
- Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders.Cancers · 2022Review
- Review
- Enteropathy-Associated T cell Lymphoma.Current hematologic malignancy reports · 2021Review
- Primary extranodal natural Killer/T-cell lymphoma in a child in the colon: A case report.Medicine · 2021Article
- Significance of clonal rearrangements of lymphocyte antigen receptor genes on the prognosis of chronic enteropathy in 22 Shiba dogs.The Journal of veterinary medical science · 2017Article
- Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges.Ecancermedicalscience · 2017Article
- Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature.Diagnostic pathology · 2016Review
- Type I enteropathy-associated T-cell lymphoma in the colon of a 29-year-old patient and a brief literature review.OncoTargets and therapy · 2016Article
- Surgery in (pre)malignant celiac disease.World journal of gastroenterology · 2015Article
- Rare gastrointestinal lymphomas: The endoscopic investigation.World journal of gastrointestinal endoscopy · 2015Review
- Hemophagocytic Lymphohistiocytic Syndrome and Enteropathy-Associated T-cell Lymphoma in a Patient with Refractory Celiac Disease.ACG case reports journal · 2014Article
- A case of colon perforation due to enteropathy-associated T-cell lymphoma.World journal of gastroenterology · 2013Article
- Clinically undiagnosed enteropathy associated T-cell lymphoma type II presenting with prolonged lower gastrointestinal tract symptoms: report of an autopsy case and review of diagnostic challenges and clinicopathological correlation.Journal of gastrointestinal oncology · 2013Article
- Celiac disease and autoimmune-associated conditions.BioMed research international · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteropathy-associated T-cell lymphoma (EATL) is a rare non-Hodgkin lymphoma of T-cell origin. The recent 2008 World Health Organization classification of hematologic malignancies distinguishes between two types of EATL. The disease is associated with celiac disease, particularly with its late, adult onset. Currently, there are no standardized diagnostic or treatment protocols for EATL, mostly because of its rarity. Historically, the patients have been treated with anthracycline-based chemotherapy with or without surgery. The outcome of patients with EATL treated with these approaches is poor. The reported death rates in the biggest studies are approximately 80-84%, with median progression-free survival (PFS) of 3.4-6.0 months and overall survival of 7.1-10.0 months. The 5-year PFS ranged from 3.2% to 18% and OS from 19.7% to 20%. The results of a novel induction regimen with ifosfamide, etoposide, and epirubicin alternating with intermediate-dose methotrexate followed by autologous stem cell transplantation (ASCT) are more promising, with a 5-year PFS of 52% and OS of 60%. The alternative approach, with a more common induction with cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone followed by ASCT has also delivered promising results, with a 3-year PFS of 52% and OS of 47%. This review summarizes recently published data on epidemiology and clinical features, as well as standard and novel treatments including high-dose chemotherapy with ASCT and their outcome in EATL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.